CLINICAL TRIALS PROFILE FOR KAPVAY

All Clinical Trials for KAPVAY

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00588354 ↗	Epidural Clonidine for Lumbosacral Radiculopathy	Terminated	National Center for Research Resources (NCRR)	N/A	2006-10-01	This was a randomized, blinded study of transforaminal epidural injection of clonidine versus a similar injection of corticosteroid for acute lumbosacral radiculopathy. The hypothesis was that clonidine will be as effective as steroid for this condition.
NCT00588354 ↗	Epidural Clonidine for Lumbosacral Radiculopathy	Terminated	Mayo Clinic	N/A	2006-10-01	This was a randomized, blinded study of transforaminal epidural injection of clonidine versus a similar injection of corticosteroid for acute lumbosacral radiculopathy. The hypothesis was that clonidine will be as effective as steroid for this condition.
NCT00884832 ↗	A Placebo-Controlled Study of Clonidine for Fecal Incontinence.	Completed	National Center for Research Resources (NCRR)	Phase 2	2008-10-01	Fecal incontinence is the involuntary leakage of stool from the anus. Doctors at Mayo Clinic are doing a research study to assess the effects of a medication, clonidine, on fecal incontinence and rectal functions in women. Clonidine has been approved by the Food and Drug Administration (FDA) for treating high blood pressure, but not for treating incontinence and rectal functions. The hypothesis of this study is clonidine will improve fecal incontinence, increase rectal capacity and reduce rectal sensation to a greater extent than placebo in women.
NCT00884832 ↗	A Placebo-Controlled Study of Clonidine for Fecal Incontinence.	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	2008-10-01	Fecal incontinence is the involuntary leakage of stool from the anus. Doctors at Mayo Clinic are doing a research study to assess the effects of a medication, clonidine, on fecal incontinence and rectal functions in women. Clonidine has been approved by the Food and Drug Administration (FDA) for treating high blood pressure, but not for treating incontinence and rectal functions. The hypothesis of this study is clonidine will improve fecal incontinence, increase rectal capacity and reduce rectal sensation to a greater extent than placebo in women.
NCT00884832 ↗	A Placebo-Controlled Study of Clonidine for Fecal Incontinence.	Completed	Mayo Clinic	Phase 2	2008-10-01	Fecal incontinence is the involuntary leakage of stool from the anus. Doctors at Mayo Clinic are doing a research study to assess the effects of a medication, clonidine, on fecal incontinence and rectal functions in women. Clonidine has been approved by the Food and Drug Administration (FDA) for treating high blood pressure, but not for treating incontinence and rectal functions. The hypothesis of this study is clonidine will improve fecal incontinence, increase rectal capacity and reduce rectal sensation to a greater extent than placebo in women.
NCT01439126 ↗	Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder	Completed	Concordia Pharmaceuticals Inc., Barbados	Phase 4	2011-08-01	The purpose of this study is to determine the long-term efficacy and safety of KAPVAY™ (clonidine hydrochloride) extended-release in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
NCT02362256 ↗	The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism	Completed	Vilnius University	N/A	2014-05-01	The aim of this study is to investigate which method of naltrexone induction during rapid opioid detoxification causes stronger stress response and has a higher influence on opioid abstinence caused by opioid induction.

Clinical Trial Conditions for KAPVAY

Condition Name

Condition Name for KAPVAY
Intervention	Trials
Attention Deficit Hyperactivity Disorder	1
Fecal Incontinence	1
Lumbar and Other Intervertebral Disc Disorders With Radiculopathy	1
Opiate Addiction	1

Condition MeSH

Condition MeSH for KAPVAY
Intervention	Trials
Intervertebral Disc Degeneration	1
Opioid-Related Disorders	1
Hyperkinesis	1
Attention Deficit Disorder with Hyperactivity	1

Clinical Trial Locations for KAPVAY

Trials by Country

Trials by Country for KAPVAY
Location	Trials
United States	3
Lithuania	1

Trials by US State

Trials by US State for KAPVAY
Location	Trials
Minnesota	2
Pennsylvania	1

Clinical Trial Progress for KAPVAY

Clinical Trial Phase

Clinical Trial Phase for KAPVAY
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	1
N/A	3

Clinical Trial Status

Clinical Trial Status for KAPVAY
Clinical Trial Phase	Trials
Completed	3
Terminated	2
Withdrawn	1

Clinical Trial Sponsors for KAPVAY

Sponsor Name

Sponsor Name for KAPVAY
Sponsor	Trials
National Center for Research Resources (NCRR)	2
Mayo Clinic	2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	1

Sponsor Type

Sponsor Type for KAPVAY
Sponsor	Trials
Other	7
NIH	3
Industry	1

KAPVAY (clonidine HCl ER): Clinical Trials Update, Market Analysis, and Projection

Last updated: May 1, 2026

What is KAPVAY and what is the latest clinical development posture?

KAPVAY is clonidine hydrochloride extended-release (ER). It is approved for attention-deficit/hyperactivity disorder (ADHD) in the pediatric population. Public clinical-trial visibility for KAPVAY is limited versus newer ADHD agents, with most activity centered on label-maintenance studies, specific patient subgroups, and comparative/real-world use rather than broad phase-3 pipelines.

How have clinical trials evolved for KAPVAY?

Publicly visible KAPVAY development has historically focused on:

• establishing ER clonidine efficacy and safety in pediatric ADHD populations
• dose-optimization and discontinuation/titration tolerability
• expanded evidence supporting long-term symptom control in ADHD

Clinical evidence structure (high level)

• Core efficacy: pediatric ADHD trials designed around symptom reduction endpoints typical for stimulant and non-stimulant ADHD classes.
• Safety: cardiovascular monitoring focus due to clonidine class effects (hypotension, bradycardia), plus sedation and somnolence surveillance.
• Persistence: studies that inform “stay on medication” and discontinuation effects.

Current update (public development signals)

Recent years show no dominant late-stage (phase 3) public readout cycle associated with a major new KAPVAY indication or reformulation. Clinical activity that remains visible tends to be:

• protocol continuation and periodic reporting
• registry-based follow-up
• secondary analyses and safety surveillance

This positioning matters because it implies the drug’s near-to-mid term growth is more dependent on market access, payer contracting, and competitive dynamics than on a fresh phase-3 evidence step.

What does the market look like for clonidine ER in ADHD?

Market context: where KAPVAY competes

KAPVAY competes within the pediatric ADHD non-stimulant segment and also indirectly with stimulant classes because prescribers choose among:

• stimulant monotherapy and combinations
• non-stimulants (including alpha-2 agonists such as clonidine ER and guanfacine ER)
• behavioral therapy add-ons

Competitive pressure inside the class

The key competitive comparator is guanfacine ER (another alpha-2 agonist), plus broader pressure from long-acting stimulants and newer ADHD formulations. Within payer formularies, this creates a pricing and access environment in which:

• “must-try” steps and prior authorization can constrain utilization
• switching between alpha-2 agonists can occur at prescriber discretion when coverage or tolerability changes
• generic erosion is a defining factor for older branded products depending on patent and exclusivity status

Is KAPVAY protected, or is it exposed to generic erosion?

KAPVAY is a long-established brand. For older ADHD brands, market share often declines as generic extended-release clonidine and class alternatives expand. For KAPVAY specifically, the practical business question is formulary position, copay and step therapy, and whether competitors have lower net cost at the PBM level.

How should investors and R&D leaders project sales for KAPVAY?

A practical projection for KAPVAY should be built on three drivers:

1. Net pricing and rebate erosion (market access and PBM contracting)
2. Utilization trend (pediatric ADHD diagnosis and persistence, plus patient switching within alpha-2 agonists)
3. Competitive substitution (stimulants and guanfacine ER)

Projection framework (scenario-based)

Because late-stage clinical catalysts are not evident from public development posture, a reasonable projection ties KAPVAY’s outlook to market-access and competition rather than to new indication approvals.

Base case assumptions

• utilization is stable-to-down in absolute terms due to competitive substitution
• market share shifts modestly between clonidine ER and guanfacine ER depending on payer strategy
• pricing pressure persists as class competition increases

Downside assumptions

• continued payer step edits for alpha-2 agonists
• increased generic and alternative channel availability (net cost advantages)
• lower persistence after initial titration due to sedation/somnolence and cardiovascular monitoring burden

Upside assumptions

• improved formulary access at major PBMs
• evidence-driven uptake in ADHD subpopulations where alpha-2 agonists are preferred (sleep comorbidity, aggression/impulsivity symptom clusters, or stimulant intolerance)
• improved patient adherence via dosing education and standardized titration protocols

What the model implies

• Without a late-stage clinical catalyst, growth is unlikely to outpace class substitution.
• The most plausible outcome is gradual volume pressure offset by contract-driven stability for a period, then further erosion.

What competitive moves matter most over the next 24 to 48 months?

Payer and channel actions (what to watch)

• formulary tier changes for non-stimulant ADHD
• prior authorization tightening or loosening for clonidine ER
• PBM incentives favoring guanfacine ER versus clonidine ER
• changes to step therapy protocols for pediatric ADHD

Prescriber behavior (what to watch)

• substitution between alpha-2 agonists when sedation/cardiovascular tolerability differs by patient
• continuation after initiation: a key determinant of long-term annual prescription totals for chronic ADHD meds

Where are the clinical value levers for KAPVAY today?

KAPVAY’s clinical differentiation is typically framed around patient-level fit rather than novel mechanisms:

• alpha-2 adrenergic effects for ADHD symptom clusters
• potential utility for pediatric patients with comorbid sleep or behavioral dysregulation where clinicians prefer alpha-2 agonists over stimulants
• long-acting ER dosing that supports once-daily adherence

Key Takeaways

• KAPVAY is clonidine ER for pediatric ADHD and competes in a crowded non-stimulant space dominated by alpha-2 agonists and stimulant-based therapies.
• Public clinical-trial visibility suggests no current dominant late-stage development engine, which makes commercial trajectory primarily dependent on payer access, pricing, and substitution dynamics.
• Market projection should emphasize net pricing/rebate erosion and competitive switching between clonidine ER and guanfacine ER, plus broader substitution from stimulants.
• The most likely outlook is stable-to-declining utilization over time absent a new regulatory or clinical catalyst, with any upside tied to formulary access gains.

FAQs

1) What is KAPVAY’s main clinical use?

KAPVAY (clonidine ER) is approved for pediatric ADHD.

2) What class risks influence KAPVAY prescribing?

Alpha-2 agonist class effects drive monitoring for hypotension, bradycardia, and sedation/somnolence.

3) Who does KAPVAY compete against in ADHD?

It competes against stimulant ADHD treatments and within non-stimulants against guanfacine ER.

4) Does KAPVAY have ongoing late-stage trials that could shift valuation?

Publicly, KAPVAY does not show clear visibility of a major late-stage phase-3 catalyst cycle; near-term dynamics appear driven by market access and competition rather than new indication expansion.

5) What drives KAPVAY sales most in the next 2 to 4 years?

Payer formulary status, prior authorization rules, PBM contracting, net pricing, and persistence after initiation are the dominant drivers.

---

References

[1] FDA. KAPVAY (clonidine hydrochloride) extended-release tablets prescribing information. U.S. Food and Drug Administration. (Latest available label accessed via FDA).